NCT01931241View on ClinicalTrials.gov

Safety Study of Bile Acid to Treat Hypercholesteremia

PHASE1UnknownINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions

Hypercholesterolemia

Interventions

DRUG

AHRO-001

Cohort 1: 500 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 2: 750 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 3: 1000 mg/dose, given as a single dose then as bid x7days and tid x7days Cohort 4: 21 days dosing given at best tolerated dose determined by cohorts 1-3 Cohort 5: 12 wks dosing given at best tolerated dose determined by cohorts 1-4

Trial Locations (1)

Unknown

City Hospital #15, Moscow